Prove your COVID-19 vaccine efficacy with ease
Share your contact details to book a meeting with our experts
Conventional Neutralizing Antibody tests such as the Plaque Reduction Neutralization Test (PRNT) for SARS-CoV-2 pose several challenges in vaccine trials. These include the need to handle a live virus (which requires a BSL3 containment facility) and tedious and time-consuming processes for running the assays.
To overcome these challenges, Syngene has developed COVID-19 assays comprising surrogate NAb and T-cell assays, which can be run in BSL-2 labs. Running these assays is also less tedious and time-consuming.
Why Syngene
Sensitivity, specificity comparable to gold standard PRNT assays
BSL-3 lab NOT required for running Syngene's COVID-19 NAb assay
Quick turn-around-time; less tedious processes
Assays available in
ELISA format
Syngene’s COVID-19 Assays
Neutralizing Antibody (NAb) assay
Syngene offers GLP validated, surrogate Neutralizing Antibody (NAb) assay in ELISA format. This has been developed using soluble ACE2 and labelled RBD at Syngene. The assay shows >95% sensitivity and specificity when compared to the gold standard PRNT assay.
- The assay can be used for the following:
- Monitor vaccine efficacy
- Correlate disease severity with immunity
- Pre-screen plasma donors
- Community-based immune surveillance
T-cell assay
Syngene has also developed a T-cell assay on Luminex platform against ~100 overlapping peptides of the SARS COV2 S1 protein. T-cells are critical for mounting a memory response to re-infection, among others.
- Our T-cell assay offers the following advantages:
- Helps to evaluate single or multiple cytokines
- Works well with both human PBMCs and whole blood
- Peptides from other viral proteins can be considered in the assay, along with a choice of other cytokines
- Assay can be converted to ELISA format
- NAb assay can be used in conjunction with the T-Cell for vaccine trials and for monitoring immune response
Serological Assay
Syngene has developed in-house, serological assay to detect COVID-19 antibodies in blood samples. This assay is available both as a service and as a Kit.
About Syngene
Syngene International Ltd. is an integrated contract research, development and manufacturing organization providing scientific services from early discovery to commercial supply. Our innovative capabilities for novel molecular entities (NMEs) cater to pharma, biotech, nutrition, animal health, consumer goods and speciality chemical companies.
Syngene has maintained a dedicated focus on combatting COVID-19 by providing a range of services in the diagnostics space. These include developing SARS-COV-2 reagent proteins, RT-PCR primers and probes, SARS-COV-2 in-vitro and in-vivo research tools, custom oligos defined by our customers, as well as those mentioned in protocols recommended by WHO, CDC and ICMR and more.
Partner with Syngene to fast track your COVID-19 research programs!